These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23139382)

  • 1. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?
    Wielens J; Headey SJ; Rhodes DI; Mulder RJ; Dolezal O; Deadman JJ; Newman J; Chalmers DK; Parker MW; Peat TS; Scanlon MJ
    J Biomol Screen; 2013 Feb; 18(2):147-59. PubMed ID: 23139382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM
    Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design.
    Rhodes DI; Peat TS; Vandegraaff N; Jeevarajah D; Le G; Jones ED; Smith JA; Coates JA; Winfield LJ; Thienthong N; Newman J; Lucent D; Ryan JH; Savage GP; Francis CL; Deadman JJ
    Antivir Chem Chemother; 2011 Mar; 21(4):155-68. PubMed ID: 21602613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences in fragment-based lead discovery.
    Hubbard RE; Murray JB
    Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75.
    De Luca L; Barreca ML; Ferro S; Christ F; Iraci N; Gitto R; Monforte AM; Debyser Z; Chimirri A
    ChemMedChem; 2009 Aug; 4(8):1311-6. PubMed ID: 19565598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based screening using surface plasmon resonance technology.
    Perspicace S; Banner D; Benz J; Müller F; Schlatter D; Huber W
    J Biomol Screen; 2009 Apr; 14(4):337-49. PubMed ID: 19403917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of B. anthracis N(5)-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening.
    Lei H; Jones C; Zhu T; Patel K; Wolf NM; Fung LW; Lee H; Johnson ME
    Bioorg Med Chem; 2016 Feb; 24(4):596-605. PubMed ID: 26740153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.
    Wielens J; Headey SJ; Jeevarajah D; Rhodes DI; Deadman J; Chalmers DK; Scanlon MJ; Parker MW
    FEBS Lett; 2010 Apr; 584(8):1455-62. PubMed ID: 20227411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening Ligands by X-ray crystallography.
    Davies DR
    Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of novel allosteric peptide inhibitors of HIV integrase identify new interactions at the LEDGF binding site.
    Rhodes DI; Peat TS; Vandegraaff N; Jeevarajah D; Newman J; Martyn J; Coates JA; Ede NJ; Rea P; Deadman JJ
    Chembiochem; 2011 Oct; 12(15):2311-5. PubMed ID: 21850718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based drug design.
    Feyfant E; Cross JB; Paris K; Tsao DH
    Methods Mol Biol; 2011; 685():241-52. PubMed ID: 20981527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical aspects of NMR-based fragment screening.
    Lepre CA
    Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based discovery of focal adhesion kinase inhibitors.
    Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels.
    Hämäläinen MD; Zhukov A; Ivarsson M; Fex T; Gottfries J; Karlsson R; Björsne M
    J Biomol Screen; 2008 Mar; 13(3):202-9. PubMed ID: 18270366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of small molecule HIV-1 integrase dimerization inhibitors.
    Tintori C; Demeulemeester J; Franchi L; Massa S; Debyser Z; Christ F; Botta M
    Bioorg Med Chem Lett; 2012 May; 22(9):3109-14. PubMed ID: 22483582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
    Danielson UH
    Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.